Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Journal of Clinical Oncology · 20.07.2024 · 42 (21) · 2527-2536
DOI: 10.1200/jco.23.02066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2024. Verfasst von Saurabh Zanwar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and MYD88 L265P mutation is now frequently assessed at diagnosis, warranting reexamination of the prognostic parameters. PATIENTS AND METHODS We reviewed records of 889 treatment-naïve patients with active WM, consecutively seen between January 01, 1996, and December 31, 2017, to identify clinical predictors of overall survival (OS) in univariate analyses. Patients with complete data for the parameters significant on the univariate analyses (n = 341) were included in a multivariable analysis to derive a prognostic model, subsequently validated in a multi-institutional cohort. RESULTS In the derivation cohort (n = 341), age (hazard ratio [HR], 1.9 [95% CI, 1.2 to 2.1]; P = .0009), serum lactate dehydrogenase (LDH) above upper limit of normal (HR, 2.3 [95% CI, 1.3 to 4.5]; P = .007), and serum albumin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France.
- University College of London, London, United Kingdom.
- Dana-Farber Cancer Institute, Boston, MA.
- Division of Hematology, Mayo Clinic, Scottsdale, AZ.
ORCID-Profile: Saurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, Jithma P Abeykoon, Patrizia Mondello, Shaji Kumar, Shayna Sarosiek, Jonas Paludo, Ricardo Parrondo, Angela Dispenzieri, Eli Muchtar, Sikandar Ailawadhi, Robert A Kyle, Alain Delmer, Morie A Gertz, Steven P Treon, Stephen M Ansell, Jorge J Castillo, Prashant Kapoor
Zitieren
APA
Zanwar, S., Le-Rademacher, J., Durot, E., D'Sa, S., Abeykoon, J. P., Mondello, P., Kumar, S., Sarosiek, S., Paludo, J., Chhabra, S., Cook, J. M., Parrondo, R., Dispenzieri, A., Gonsalves, W. I., Muchtar, E., Ailawadhi, S., Kyle, R. A., Rajkumar, S. V., Delmer, A., …, & Kapoor, P. (2024). Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology, 42(21), 2527-2536. https://doi.org/10.1200/jco.23.02066
Vancouver
Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, et al. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology. 2024;42(21):2527-2536. doi:10.1200/jco.23.02066
BibTeX
@article{Zanwar2024,
author = {Zanwar, Saurabh and Le-Rademacher, Jennifer and Durot, Eric and D'Sa, Shirley and Abeykoon, Jithma P and Mondello, Patrizia and Kumar, Shaji and Sarosiek, Shayna and Paludo, Jonas and Chhabra, Saurabh and Cook, Joselle M and Parrondo, Ricardo and Dispenzieri, Angela and Gonsalves, Wilson I and Muchtar, Eli and Ailawadhi, Sikandar and Kyle, Robert A and Rajkumar, S Vincent and Delmer, Alain and Fonseca, Rafael and Gertz, Morie A and Treon, Steven P and Ansell, Stephen M and Castillo, Jorge J and Kapoor, Prashant},
title = {Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {21},
pages = {2527--2536},
doi = {10.1200/jco.23.02066}
}
EUVIMED